Title	The effect of dopamine on adult hippocampal neurogenesis
Author(s)	Takamura, Naoki; Nakagawa, Shin; Masuda, Takahiro; Boku, Shuken; Kato, Akiko; Song, Ning; An, Yan; Kitaichi, Yuji; Inoue, Takeshi; Koyama, Tsukasa; Kusumi, Ichiro
Citation	Progress in neuro-psychopharmacology & biological psychiatry, 50, 116-124 https://doi.org/10.1016/j.pnpbp.2013.12.011
Issue Date	2014-04-03
Doc URL	http://hdl.handle.net/2115/55132
Type	article (author version)
File Information	Prog Neuropsychopharmacol Biol Psychiatry_50_116-124.pdf

[Instructions for use](#)

The effect of dopamine on adult hippocampal neurogenesis

Naoki Takamura^{a, b}, Shin Nakagawa^{* a}, Takahiro Masuda^b, Shuken Boku^a, Akiko Kato^a,
Song Ning^a, AN Yan^a, Yuji Kitaichi^a, Takeshi Inoue^a, Tsukasa Koyama^a and Ichiro
Kusumi^a

a: Department of Psychiatry, Hokkaido University Graduate School of Medicine,
Sapporo, Japan
b: Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka,
Japan

*Correspondence should be addressed to Shin Nakagawa, MD, PhD; Department of
Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7,
Kita-ku, Sapporo 060-8638, Japan. TEL: +81-11-706-5160; Fax: +81-11-706-5081;
E-mail: snakaga@med.hokudai.ac.jp

Abstract: 198, manuscript: 4436, References 49: Figures: 6, Tables: 2,

Supplementary materials: 0

Abbreviated Running Title: Effect of DA on adult hippocampal neurogenesis

Key Words: D1-like receptor; D2-like receptor; progenitor cell; stem cell;
antidepressant drug

Abbreviations: ADP; adult dentate gyrus-derived neural precursor cells, bFGF; basic fibroblast growth factor, BrdU; 5-bromo-2-deoxyuridine, CNTF; ciliary neurotrophic factor, FBS; fetal bovine serum, GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, GCL; granule cell layer, GFAP; glial fibrillary acidic protein, HBSS; hanks balanced salt solution, NPC; neural precursor cells, PBS; phosphate buffered saline, PS; penicillin-streptomycin, SGZ; subgranular zone, SVZ; subventricular zone, SSRI; selective serotonin reuptake inhibitor, Tuj-1; Neuron-specific class III β -tubulin

1
2
3 **1. Introduction**
4
5

6 In the adult mammalian brain, neurogenesis mainly occurs in two regions,
7
8
9 subventricular zone (SVZ) situated through the lateral wall of the lateral ventricles and
10
11
12 subgranular zone (SGZ) in the dentate gyrus (DG) of hippocampus (Kempermann,
13
14
15 2006). Neural precursor cells (NPCs) reside in the SGZ proliferate, survive, and
16
17
18 differentiate into neuron and glia. This differential step of neurogenesis is affected by
19
20
21 many factors, including environment, stress, hormone and drugs (Dranovsky and Hen,
22
23
24 2006, Duman et al., 2001). Stress of various kinds, are considered to be a risk factor of
25
26
27 depression, decrease the proliferation of NPCs (Gould et al., 1997; Pham et al., 2003).
28
29
30
31 As clinical therapeutic effect, chronic treatment with different classes of antidepressant
32
33
34 drugs such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants
35
36
37 (TCAs), and noradrenalin reuptake inhibitors increase the proliferation (Airan et al.,
38
39
40 2007, Malberg et al., 2000, Santarelli et al., 2003). It is also reported that suppression of
41
42
43 hippocampal neurogenesis by the irradiation prevents anti-depressive effects induced by
44
45
46 fluoxetine or imipramine treatment (Airan et al., 2007, Santarelli et al., 2003). These
47
48
49 results suggest neurogenesis might be involved in the action mechanism of
50
51
52 antidepressant drugs and/or the pathophysiology of depression. However, it remains
53
54
55 unknown in detail how antidepressant drugs regulate adult hippocampal neurogenesis
56
57
58
59
60
61
62
63
64
65

1
2
3 and how the modified neurogenesis shows anti-depressive effects.
4
5

6 Dopamine (DA) is involved in the regulation of motivation, volition,
7
8
9 interest/pleasure, and attention/concentration, all of which are likely to be impaired in
10
11
12 depressed patients. Several previous reports suggest that depression may often be
13
14
15 accompanied by a relative hypo-dopaminergic state (Papakostas, 2006). Roy et al.
16
17
18 (1985) reported lower cerebrospinal fluid of homovanilic acid, a chief metabolite of DA.
19
20
21
22 Several neuroimaging studies showed increased D2/D3-receptor and decreased DA
23
24
25 transporter bindings in some brain regions of depressive patients (D'Haenen H and
26
27
28 Bossuyt, 1994, Meyer et al., 2001, Shah et al., 1997). Therefore, the dopaminergic
29
30
31 system may be a target for the pharmacological treatment of depression. In fact, it has
32
33
34
35 been reported that DA receptor agonists such as bromocriptine, pramipexole or the
36
37
38 combination therapy of them with antidepressants may be beneficial effects in the
39
40
41 treatment for refractory and bipolar depression (Aiken, 2007, Inoue et al., 2010, Inoue et
42
43
44 al., 1996).
45
46

47 Several studies suggested that DA controls the differential steps of adult hippocampal
48
49
50 neurogenesis. SGZ receives dopaminergic projection from ventral tegmental area
51
52
53 (Baker et al., 2004, Gasbarri et al., 1997, Hoglinger et al., 2004). Experimental
54
55
56
57 depletion of DA in rodents decreased the cell proliferation and survival of NPCs in SGZ
58
59
60
61
62
63
64
65

(Hoglinger et al., 2004, Khaindrava et al., 2011). Furthermore, postmortem study showed that number of NPCs was reduced in SGZ of patients suffered from Parkinson disease (Borta and Hoglinger, 2007). However, dopaminergic modulation of adult hippocampal neurogenesis has not been investigated well.

NPCs in adult hippocampus are classified into stem/progenitor cells of four types based on stages of neural development (Kempermann, 2006). We have recently established the culture system of adult rat dentate gyrus-derived neural precursor cells (ADPs), which correspond to type 2a early progenitor cells in the adult hippocampus (Boku et al., 2009, Masuda et al., 2012). Encinas (2006) showed that fluoxetine increased the early progenitor cell classified as type 2 *in vivo* study. In the present study, to clarify the direct effect of DA on NPCs, we examined the effect of DA on the proliferation of ADPs. In addition, we examined the effect of DA receptor agonists on adult rat hippocampal neurogenesis *in vivo*. These results showed that DA promoted the increase of ADPs via D1-like receptor and D1-like receptor agonist promoted the survival of newborn cells in the adult hippocampus. On the other hand, D2-like receptor agonist did not affect both proliferation and survival.

2. Material and methods

2.1. Animals

Male Sprague-Dawley (SD) rats (7 weeks old) were obtained from Japan SLC, Inc. (Shizuoka, Japan). The rats were housed in groups of three or four in a temperature-controlled environment (22 ± 1 °C) with free access to food and water. The subjects were maintained on a 12 h light/ dark cycle (light phase; 06:00-18:00). The experiments began after 1 week for an acclimatization period.

All experiments were approved by the Hokkaido University School of Medicine Animal Care and Use Committee and were in compliance with the Guide for the Care and Use of Laboratory Animals.

2.2. Drugs

Dopamine hydrate was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). ($\pm$)-SKF38393, ($\pm$)-SKF-81297, quinpirole, pramipexole dihydrochloride and R-SCH23390 were purchased from Sigma-Aldrich Corp. (St. Louis, MO). Bromocriptine mesilate was donated by Nihon Ciba-Geigy K.K (Tokyo, Japan). Sulpiride was donated by Fujisawa Pharmaceutical Co. Ltd (Osaka, Japan). Each binding affinities of compounds for D1-like and D2-like receptor of rat striatum was described at Table 1 (Andersen, 1988, Chen et al., 2011, Mottola et al., 1992, Neumeyer et al., 2003).

2.3. Isolation and culture of ADP

ADPs were isolated from DG of adult male SD rats (8 weeks) as described in a previous report (Boku et al., 2009). Briefly, rats were deeply anesthetized with sodium pentobarbital (Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan) and were then decapitated. The brains were removed from 8 rats immediately and were placed in cold Hank's balanced salt solution. The coronal sections with a thickness of 1mm were cut using brain slicer (Muromachi Kikai Co. Ltd., Tokyo, Japan). The DG region of hippocampus was dissected carefully under a dissecting microscope to exclude all regions containing subependymal tissues. The dissected DG tissue was minced with a scalpel blade and digested using a mixture of 2.5 U/ml papain (Worthington Biochemical Corp., Lakewood, NJ), 1 U/ml dispase II (F. Hoffman La Roche Ltd., Indianapolis, IN) and 250 U/ml Deoxyribonuclease I (Worthington) in a water bath at 37 °C for 30 min. The cell mixture was passed through a 70 µm cell strainer. The fraction containing ADP was separated using Percoll gradient centrifugation (GE Healthcare, Uppsala, Sweden). After separation, the cells were washed and suspended with DMEM/F12 medium (Sigma-Aldrich) containing 10% fetal bovine serum (FBS; Invitrogen Corp., Carlsbad, CA) and 1 % penicillin/streptomycin (Invitrogen). The

suspension cells were plated onto a non-coated plate. After overnight culture at 37°C, 5% CO₂, the medium was exchanged for proliferation medium consisting of Neurobasal (Invitrogen), B27 supplement minus vitamin A (Invitrogen), 2 mM L-Glutamine (Invitrogen), 1% penicillin/streptomycin, and 20 ng/ml basic fibroblast growth factor (Invitrogen). Subsequently, half of the medium was change new proliferation medium every two or three days. At the 80-90% confluency, cells were passaged by trypsinization onto poly L-ornithine-laminin-coated dishes. The cell density for plating was approximately 1×10^4 cells /cm².

2.4. Cell Counting of ADP

Viable cells were quantitated using an Alamar Blue assay, which is a rapid and simple non-radioactive assay. 1×10^4 cells were seeded on laminin- ornithine coated 96-well plates in 100 µl/well of proliferation medium. After overnight incubation, to examine the effect of DA receptor ligands on ADP proliferation, cells were treated with each drug at each concentration for 3 days. To examine the effect of DA receptor antagonists on DA-promoted ADP proliferation, antagonists were applied to culture medium 1h before 30 µM of DA was added and the cells were cultured for 3 day. Three days after the treatment, 10 µl/well of Alamar Blue solution (Invitrogen) was added to

1
2
3 medium, and cells were incubated at 37°C for 3 h. Then the absorbance was measured
4
5
6 using a Varioskan Flash (Thermo Fisher Scientific Inc., Waltham, MA) microplate
7
8
9 reader at 570 and 600 nm, and cell number based on percentage reduction of Alamar
10
11
12 Blue was calculated as described in the manufacture's protocol. Although the DA
13
14
15 concentration in the extracellular fluid of the rat hippocampus is under normal
16
17
18 conditions are reported as 0.1 nM (Simpson et al., 2001), micromolar concentration
19
20
21 range of DA was used in *in vitro* study evaluating the effect of DA on proliferation of
22
23
24 the cell derived from SVZ (Hoglinger et al., 2004, O'Keefe et al., 2009b). Therefore,
25
26
27 we used DA at broad concentrations of 1-100 µM. The ranges of other compounds used
28
29
30 in this study were determined by preliminary experiments.
31
32
33

34 35 36 37 38 *2.5. RNA extraction and reverse transcription –polymerase chain reaction (RT-PCR)*

39
40

41 Total RNA was extracted from cells with RNeasy Extraction kit (Qiagen Inc., Hilden,
42
43
44 Germany). Total RNA was converted to cDNA with Quantitect Reverse Transcription
45
46
47 kit (Qiagen). Polymerase chain reaction (PCR) was performed with AmpliTaq Gold 360
48
49
50 master mix (Applied biosystems, Foster City, CA) in the GeneAmp PCR system 9700
51
52
53 (Applied biosystems). The conditions of PCR were: 95°C for 10 min, followed by 40
54
55
56 cycle of 95°C for 30 s, 60°C for 30 s and 72°C for 1 min, and finally 72°C for 7 min.
57
58
59
60
61
62
63
64
65

1
2
3 The sequences of forward and reverse primers and product size are presented in Table 2.
4
5

6 PCR products were analyzed in a 3% agarose gel in Tris-boric acid EDTA buffer
7
8

9 containing ethidium bromide. Images of gels were obtained using image analysis
10
11

12 software (Kodak 1D; Eastman Kodak Company, Rochester, NY).
13
14
15
16
17
18

19 *2.6. In vivo experimental design and sample collection* 20 21

22 For the experiment to evaluate the drug effect on the proliferation, rats (8 weeks old)
23
24 were either administrated ($\pm$)-SKF38393 (10 or 30 mg/kg), pramipexole (0.3 or 1
25
26 mg/kg) or saline daily by intraperitoneal (i.p.) injection for 21 days. 24 h after the last
27
28 drug administration, rats were once received injection of 5-bromo-3'-deoxyuridine
29
30 (BrdU, 75 mg/kg, i.p.).
31
32
33
34
35
36

37 For the experiment to evaluate the drug effect on the cell survival, rats were received
38
39 injection of BrdU (75 mg/kg, i.p.) once. From next day, rats were administrated either
40
41 ($\pm$)-SKF38393 (10 or 30mg/kg, i.p.), pramipexole (0.3 or 1 mg/kg) or saline once a day
42
43
44
45
46 for 21 days. The doses of drugs used in this study were based on previous reports
47
48 (Cooper et al., 1990, D'Aquila et al., 2000, Gambarana et al., 1995, Winner et al., 2009).
49
50
51
52
53
54 24 h after the last injection, rats were anaesthetized with sodium pentobarbital and
55
56
57 transcardinally perfused with 0.1 M cold phosphate-buffered saline (PBS), followed by
58
59
60
61
62
63
64
65

1
2
3 4% cold paraformaldehyde. The brains were removed and post-fixed overnight in 4%
4
5
6 paraformaldehyde and cryoprotected in 30% sucrose.
7
8
9

10 11 12 13 *2.7. Immunohistochemistry* 14 15

16 A freezing microtome was used to collect serial coronal 30 µm sections through
17
18 the entire hippocampus. Every twelfth section was slide-mounted for peroxidase BrdU
19
20 immunolabeling. The sections were incubated 0.01 M citric acid at 90 °C, digested in
21
22 trypsin (0.1%) in Tris buffer containing 0.1% CaCl₂ for 10 min, denatured in 2N HCl
23
24 for 30 min, blocked in 3% normal horse serum for 20 min, and incubated overnight at
25
26 4 °C with mouse monoclonal antibody against BrdU (1:50; Becton Dickinson, CA) in
27
28 PBS containing 3% normal horse serum and 0.2% Tween 20. On the next day, the
29
30 sections were incubated in biotinylated secondary antisera (IgG, 1:200; Vector
31
32 Laboratories) for 60 min, incubated in avidin-biotin-horseradish peroxidase (1:50;
33
34 Vector Laboratories) for 60 min and reacted in the solution of 3,3'-diaminobenzidine
35
36 (Vector Laboratories). The sections were counterstained with Cresyl Violet.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 *2.8. Quantitation of BrdU-labelled cells* 54 55

56 The numbers of BrdU-positive cells were counted in right side of section with a
57
58 coded one-in-twelve series section. Cells were counted as being in the SGZ if they were
59
60
61
62
63
64
65

1
2
3 touching or in the SGZ. Cells that were located more than two cells away from the SGZ
4
5
6 were counted as in the hilus. All BrdU-positive cells were counted regardless of the size
7
8
9 or shape through a 100 × objective with Olympus BX-60 (Olympus Optical, Tokyo,
10
11
12 Japan) throughout the rostrocaudal extent of granule cell layer (GCL). The total
13
14
15 numbers of BrdU positive cells were multiplied by twelve and reported as total number
16
17
18 of cells per right side region.
19
20
21
22
23
24

25 2.9. Data analysis 26

27
28 Results were expressed as the mean and standard error of the means (SEM).
29
30
31 Statistical analyses were performed using one-way ANOVA with a Dunnett's post hoc
32
33
34 test in dose-response experiments, two-way ANOVA with Dunnett's post hoc test in the
35
36
37 experiments for effect of DA receptor antagonists on DA-promoted ADP proliferation
38
39
40 and Student's t-test in the experiments for effect of SKF38393 on proliferation of NPC
41
42
43 in *vivo*. In the case that the data were not normally distributed or homogenous for
44
45
46 variance, a Kruskal-Wallis analysis followed by a Steel test for non-parametric analyses
47
48
49 was performed to detect any significant effects of treatments.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1. Effect of DA on ADP proliferation

We firstly investigated the effect of DA on ADP proliferation. One-way ANOVA showed significant difference related to treatment with dopamine on the cell number of ADPs ($F(5, 30) = 4.55$; $p = 0.0033$). *Post-hoc* analyses revealed that the cell number of ADPs was increased significantly by treatment with 30 and 100 μM DA compared to the control ($114 \pm 2\%$ ($p < 0.01$), $114 \pm 4\%$ ($p < 0.05$); Dunnett's test, respectively) (Fig. 1). This result indicated DA directly promoted the proliferation of ADPs.

3.2. mRNA expression pattern of DA receptor on ADP

DA receptors are classified into two major types, D1-like receptors (D1 and D5) and D2-like receptors (D2, D3 and D4) according to structural homologies and shared messenger cascades. To evaluate the expression pattern of DA receptors on ADPs, we performed RT-PCR analysis. The results showed that all subtypes of DA receptor mRNAs were detected (Fig. 2).

3.3. Effects of D1- and D2-like receptor antagonists on DA-promoted ADP proliferation

We next examined the effects of DA receptor antagonists (Fig. 3A, C) and the

co-administration of DA receptor antagonists with DA (Fig. 3B, D) on the cell number of ADPs. One-way ANOVA showed no difference related to treatment with neither D1-like receptor antagonist R-SCH23390 ($F(5, 18) = 0.39; p = 0.85$) nor D2-like receptor antagonist sulpiride ($F(5, 12) = 0.62; p = 0.69$) on the cell number of ADPs (Fig. 3A, C). On the other hand, two-way ANOVA showed significant difference related to treatment with R-SCH23390 on DA-increased number of ADPs ($F(4, 18) = 9.34; p = 0.0003$). *Post-hoc* analyses revealed that R-SCH23390 significantly attenuated DA-induced increase of ADPs at the dose of 10, 30 and 100 μ M ($p < 0.05$, $p < 0.01$ and $p < 0.01$; Dunnett's test, respectively) (Fig. 3B). On the contrary, sulpiride did not ($F(4, 12) = 0.85; p = 0.52$, Two-way ANOVA) (Fig. 3D).

3.4. Effects of D1- and D2-like receptor agonists on ADP proliferation

We next examined the effect of D1- and D2- like receptor agonists on the cell number of ADPs. One-way ANOVA showed significant difference related to treatment with D1-like receptor agonist ($\pm$)-SKF38393 and ($\pm$)-SKF82197 on the cell number of ADPs ($F(5, 18) = 21.7; p < 0.0001$, $F(5, 12) = 77.7; p < 0.0001$, respectively). *Post-hoc* analyses revealed that ($\pm$)-SKF38393 at doses of 100 μ M significantly increased the cell number of ADPs ($135 \pm 3\%$, $p < 0.01$; Dunnett's test) and that ($\pm$)-SKF81297 at doses of

30 μ M significantly increased ($122 \pm 2\%$, $p < 0.01$; Dunnett's test) (Fig. 4A and B). On the other hand, D2-like receptor agonist quinpirole did not ($F(5, 18) = 1.19$; $p = 0.35$, one-way ANOVA) (Fig. 4C). Moreover, D2-like receptor agonists including pramipexole ($F(5, 12) = 1.08$; $p = 0.42$, one-way ANOVA) and bromocriptine ($F(5, 12) = 8.47$; $p = 0.0012$, one-way ANOVA, $p < 0.01$; post hoc Dunnett's test) did not increase the cell number of ADPs either (Fig. 4D and E).

3.5 Effects of DA receptor agonists on proliferation of NPCs in adult rat hippocampus

DA increased the cell number of ADPs via D1-like but not D2-like receptor *in vitro*. To investigate the effects of DA receptor agonists on the proliferation of NPCs in adult hippocampus *in vivo*, rats were given ($\pm$)-SKF38393, a D1-like receptor agonist, or pramipexole, a D2-like receptor agonist, daily for 21 days, followed by the BrdU administration to label dividing cells. BrdU-labelled cells were seen more in SGZ than hilus region (Fig. 5A, B, and C). Most of them formed cluster. Student's t-test showed that treatment of ($\pm$)-SKF38393 at the dose of 10 mg/kg/day had no effect on the number of BrdU-positive cells in SGZ (4209 ± 281) ($t = 1.34$; $p = 0.20$) and hilus (1176 ± 98) ($t = 1.43$; $p = 0.17$) of DG compared to the control (3681 ± 276 in SGZ, 993 ± 82 in hilus) (Fig. 5D, E). Furthermore, treatment of ($\pm$)-SKF38393 at the dose of 30

1
2
3 mg/kg/day also had no effect on the number of BrdU-positive cells in SGZ (2125 ± 288)
4
5
6 ($t=1.11$; $p=0.28$) and hilus (682 ± 107) ($t=1.47$; $p=0.16$) of DG compared to the control
7
8
9 (1816 ± 144 in SGZ, 474 ± 76 in hilus) (Fig. 5F, G). On the other hand, treatment of
10
11
12 pramipexole at the dose of 0.3 and 1 mg/kg/day did not affect the number of
13
14
15 BrdU-positive cells in SGZ (3280 ± 401 , 2510 ± 356 , respectively) ($F(2, 15) = 1.66$;
16
17
18 $p=0.92$) and hilus (790 ± 180 , 772 ± 128 , respectively) ($F(2, 15) = 1.10$; $p=0.36$) of DG
19
20
21 compared to the control (2698 ± 392 in SGZ, 810 ± 160 in hilus) neither (Fig. 5H, I).
22
23
24
25
26
27

28 *3.6. Effects of DA receptor agonists on survival of newborn cells in adult rat* 29 30 31 *hippocampus* 32 33 34

35 We next investigated the effect of DA receptor agonists on the survival of newborn
36
37
38 cells in adult rat hippocampus. BrdU-labeled neuclei were almost round and seen
39
40
41 separately in the GCL (Fig. 6A, B, C). Kruskal-Wallis test showed significant difference
42
43
44 related to treatment with of ($\pm$)-SKF38393 on the number of BrdU-positive cells in GCL
45
46
47 ($H=9.02$; $p=0.013$) and one-way ANOVA showed significant difference related to
48
49
50 treatment with of ($\pm$)-SKF38393 on the number of BrdU-positive cells in hilus ($F(2,$
51
52
53 $24) = 3.82$; $p=0.036$, one-way ANOVA). Post-hoc analyses revealed that treatment of
54
55
56 ($\pm$)-SKF38393 at the dose of 10 and 30 mg/kg/day increased significantly the number of
57
58
59
60
61
62
63
64
65

1
2
3 BrdU-positive cells both in GCL (4653 ± 444 ($p < 0.01$), 3994 ± 396 ($p < 0.05$); Steel test,
4
5
6 respectively) and hilus (1572 ± 244 ($p < 0.05$), 1657 ± 164 , ($p < 0.05$); Dunnett's test,
7
8
9 respectively) of DG compared to the control (3033 ± 138 in SGZ, 1011 ± 103 in hilus)
10
11
12 (Fig. 6D, E). On the other hand, one-way ANOVA showed that treatment of
13
14
15
16 pramipexole at the dose of 0.3 and 1 mg/kg/day did not affect the number of
17
18
19 BrdU-positive cells in SGZ (6384 ± 409 , 5766 ± 488 , respectively) ($F(2, 15) = 0.91$;
20
21
22 $p = 0.42$) and hilus (2044 ± 208 , 1786 ± 142 , respectively) ($F(2, 15) = 0.57$; $p = 0.58$) of
23
24
25
26 DG compared to the control (5542 ± 471 in SGZ, 1788 ± 230 in hilus) (Fig. 6F, G).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4. Discussion

The aim of present study is to investigate the effect of DA on adult hippocampal neurogenesis. First, we showed that DA directly increased the cell number of ADPs. This DA-promoting effect for proliferation is consistent with *in vivo* study showing that drug-induced depletion of DA decreases NPC proliferation in SGZ of adult hippocampus (Hoglinger et al., 2004, Winner et al., 2009). ADPs expressed all subtypes of DA receptor (D1-D5) mRNAs as progenitor cells *in vivo* (Mu et al., 2011).

Next, we investigated which subtype of receptor mediated the DA-promoted ADP proliferation using pharmacological methods. D2-like receptor agonists such as bromocriptine, pramipexole or the combination therapy of them with antidepressants are effective in the treatment for refractory and bipolar depression (Aiken, 2007, Inoue et al., 2010, Inoue et al., 1996), and several preclinical studies have shown that D2-like receptor agonist promoted the proliferation of neurospheres derived from SVZ (O'Keefe et al., 2009a, Winner et al., 2009). From these findings, we expected that DA increased an ADP proliferation thorough D2-like receptor. However, the results indicated not D2-like but D1-like receptor. Several studies showed 0.3-30 μ M of DA promoted the proliferation of neurospheres derived SVZ mediated by D2-like receptor (Hoglinger et al., 2004, O'Keefe et al., 2009b). Compared with these studies, relative high concentration of DA was required to promote the proliferation of ADPs in this

1
2
3 study. This reason might be explained by the different affinities of DA for DA receptors
4
5
6 (Table. 1). DA shows a lower affinity for D1-like receptors than D2-like receptors
7
8
9 (Missale et al., 1998). Thus, higher concentration DA might be required to promote the
10
11
12 proliferation of ADPs.
13
14
15

16 We investigated the effect of DA receptor agonists on the proliferation of NPCs in
17
18 the adult rat hippocampus. While we evaluated the effect of (±)-SKF38393 and
19
20 (±)-SKF81297 *in vitro* assay, we used only (±)-SKF38393 as a D1-like agonist *in vivo*
21
22 assay. The reason that we use (±)-SKF38393 *in vivo* experiments was that
23
24
25 (±)-SKF38393 is used generally used as a D1-like receptor agonist *in vitro* and *in vivo*
26
27
28 assay. While we evaluated the effect for ADP proliferation with three D2-like receptor
29
30 agonists, pramipexole, bromocriptine and quinpirole *in vitro* experiments, we used
31
32 pramipexole for *in vivo* experiments. Among three D2-like receptor agonists we used in
33
34 this study, only bromocriptine decreased the proliferation of ADP suggesting an extra
35
36 D2-like receptor mechanism on the proliferation. Pramipexole is used for refractory
37
38 depression in clinical (Aiken, 2007) and promoted the proliferation of NPC in SVZ of
39
40 DA-depletion model (Winner et al., 2009). From these reasons, we selected pramipexole
41
42 for *in vivo* experiments. Although D1-like receptor agonists promoted the proliferation
43
44 of ADPs, chronic administration of (±)-SKF38393 had no effect on the proliferation of
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 NPCs *in vivo*. Hoglinger et al. (2004) showed that dopamine depletion of DA induced
4
5
6 the decrease of NPC in DG and it was recovered in parallel with dopaminergic
7
8
9 re-innervation. Thus, DA may play an important role in proliferation homeostasis in
10
11
12 normal animals. The maintenance medium did not contain DA in the case of culture
13
14
15 with ADPs. So, we might detect the stimulative effect of D1-like receptor agonist on
16
17
18 proliferation *in vivo* assay. On the other hand, in our *in vivo* experiments, physiological DA
19
20
21 existed in hippocampus of normal rats might put the effect of ($\pm$)-SKF38393 in the
22
23
24 shade. Chronic treatment with pramipexole also did not affect the proliferation on NPC
25
26
27 in adult hippocampus of rats. This result was consistent with *in vitro* result. As like the
28
29
30 effect of ($\pm$)-SKF38393 for proliferation *in vivo* results, there is the possibility that
31
32
33 physiological DA might put the effect of pramipexole in the shade. However, a previous
34
35
36 study showed that chronic treatment with pramipexole increases the proliferation of
37
38
39 NPC in SVZ but not in SGZ of drug-induced DA depletion model rats (Winner et al.,
40
41
42 2009). From these results, pramipexole might not affect the proliferation of NPC in DG
43
44
45 regardless of the presence of DA. Yang et al. (2008) demonstrated that treatment of
46
47
48 D2-like receptor agonist quinpirole increased the proliferation of NPCs mediated by
49
50
51 ciliary neurotrophic factor (CNTF) in glial cells of mouse hippocampus. There are some
52
53
54 differences in experimental conditions between them and us. One difference is spices
55
56
57
58
59
60
61
62
63
64
65

1
2
3 used in experiments, we used rats and Yang used mice. Recently, it is reported that
4
5
6 serotonin 1A receptor agonist increased the adult hippocampal neurogenesis in rats but
7
8
9 not mice (Arnold and Hagg, 2012). Thus, this difference is possible reason. Other
10
11
12 difference is the period of drug administration, which they used intermittent injections
13
14
15 for only 3 days. It is possible that chronic treatments induce adaptive changes in D2-like
16
17
18 receptors. Some studies evaluated the effect of haloperidol, an antipsychotic with
19
20
21 D2-like receptor antagonistic activities. Acute and chronic treatment of haloperidol
22
23
24 showed that haloperidol did not affect the proliferation of NPC in DG, while one study
25
26
27 showed an increase (Dawirs et al., 1998, Kippin et al., 2005, Malberg et al., 2000).
28
29
30 These discrepancies results in these studies might be due to difference in experiments
31
32
33 conditions including experimental design, drug dosage and species, because haloperidol
34
35
36 is not selective D2-like receptor antagonist (Bymaster et al., 1996). Thus, it is difficult
37
38
39 to determine the effect of D2-like receptor on proliferation from these studies. Another
40
41
42 study showed S33138, a selective D3 receptor antagonist, or D3 receptor knockout
43
44
45 (KO) increased the number of NPC in DG (Egeland et al., 2012). They also showed
46
47
48 interesting results that S33138 decreased the proliferation of NPC in DG of D3-KO
49
50
51 mouse. Although S33138 is selective D3 receptor antagonist, it has weak D2 receptor
52
53
54 antagonistic activity (Millan et al., 2008). Thus, D2 antagonistic activity of S33138 is
55
56
57
58
59
60
61
62
63
64
65

1
2
3 relatively enhanced in D3 KO mouse. This results suggested that blockade of D2
4
5
6 receptor decreased proliferation in DG. So, DA can act through multiple receptor subtype
7
8
9 to exert NPC. Future studies are required to evaluate the effect of each DA receptor
10
11
12 subtype for the proliferation using more selective DA receptor agonists or antagonists.
13
14
15

16 A previous study showed that DA depletion decreased cell survival in DG
17
18 (Khaindrava et al., 2011). To examine the effect of DA receptor agonists on survival of
19
20 newborn cells, BrdU was injected once followed by the administration of ($\pm$)-SKF38393
21
22 or pramipexole for 21 days. The result showed significant increase of cell number for
23
24
25 BrdU-labeled cells in chronic D1-like receptor stimulation rat compared with control.
26
27
28 The survival-promoting activity of astrocytes induced by apomorphine, a potent D1/D2
29
30 agonist, is partially mediated by D1-like receptor (Li et al., 2006). Using the primary
31
32 culture of rat striatal neurons, Amano et al. (1994) showed that DA-induced
33
34 neuroprotection against kainic acid by the increase of intercellular cAMP mediated
35
36 D1-like receptor activation. Thus, our results seem to be consistent with previous
37
38 reports.
39
40
41
42
43
44
45
46
47
48
49

50
51 Our *in vitro* and *in vivo* findings together suggest that the clinical effect of D2-like
52
53 receptor agonists for depression might not be related to hippocampal neurogenesis. It is
54
55 reported that the efficacy of fluoxetine is blocked in some, but not all, behavioral
56
57
58
59
60
61
62
63
64
65

1
2
3 paradigms in corticosterone-treated mice where hippocampal neurogenesis is abolished
4
5
6 by X-irradiation (David et al., 2009). It suggests antidepressant action is mediated by
7
8
9 both hippocampal neurogenesis-dependent and -independent mechanism. Unlike SSRI
10
11
12 and TCA, DA receptor agonists may exhibit rapid antidepressant action (Willner, 1997).
13
14
15 Furthermore, a previous study reported that the anti-depressive action of pramipexole
16
17
18 might be mediated through nucleus accumbens (Kitagawa et al., 2009). Thus, the
19
20
21 therapeutic action of pramipexole may rely on the neurogenesis-independent
22
23
24 mechanism.
25
26

27
28 At the present time, it remains unclear how activation of D1-like receptor promotes
29
30
31 some aspects of adult hippocampal neurogenesis. The major signaling cascade
32
33
34 underlying D1-like receptor is cAMP cascade. Our previous report showed that
35
36
37 noradrenaline directly increased the proliferation of ADPs via β 2 receptor (Masuda et al.,
38
39
40 2012). As with D1-like receptor, the stimulation of β 2 receptor activates Gs protein
41
42
43 coupled to adenylyl cyclase. Thus, the increase of intracellular cAMP might be one of
44
45
46 the possible mechanisms in promoting the proliferation. Inhibition of
47
48
49 phosphodiesterase-4, an enzyme that catalyzes the hydrolysis of cAMP, stimulate
50
51
52 cAMP-CREB cascade and increase the survival of newborn cells (Li et al., 2009,
53
54
55 Nakagawa et al., 2002, Sasaki et al., 2007). Therefore, cAMP cascade might be also
56
57
58
59
60
61
62
63
64
65

involved in the survival of newborn cells in the adult hippocampus thorough the activation of D1-like receptor.

5. Conclusion

Here we have shown that DA promoted the increase of ADPs via D1-like receptor and D1-like receptor agonist promoted the survival of newborn cells in the adult rat hippocampus. These results suggested that D1-like receptor might play, at least in part, a role in adult hippocampal neurogenesis and the activation of D1-like receptor might have a therapeutic potential for depression. Hippocampal neurogenesis is as a process mainly composed by proliferation, survival and differentiation on newborn cells. In this paper, we evaluated the effect of dopamine on proliferation and survival but differentiation. In further study, it is needed to evaluate the effect of dopamine on differentiation.

Conflicts of Interest

Dr. S. Nakagawa has received honoraria from GlaxoSmithKline, Eisai, Pfizer, Daiichi-Sankyo, Meiji Seika Pharma, Ono Pharmaceutical and Eli Lilly, and has received research/grant support from Dainippon Sumitomo Pharma, Pfizer, Eli Lilly, Eisai and Ono Pharmaceutical. Dr. Inoue has received honoraria from GlaxoSmithKline, Pfizer, Astellas, Eli Lilly, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Otsuka Pharmaceutical, Meiji Seika Pharma, Asahi Kasei Pharma, Sionogi, Janssen Pharmaceutical, Takeda Pharmaceutical and Yoshitomi Pharmaceutical, has received research/grant support from Otsuka Pharmaceutical, and is a member of the advisory boards of GlaxoSmithKline, Eli Lilly, Mochida Pharmaceutical and Mitsubishi Tanabe Pharma. Other authors have no potential conflicts of interests.

Acknowledgements

This work was supported in part by JSPS KAKENHI Grants Number 23591667.

Reference

Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007;68:1230-6.

Airan RD, Meltzer LA, Roy M, Gong Y, Chen H, Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. 2007;317:819-23.

Amano T, Ujihara H, Matsubayashi H, Sasa M, Yokota T, Tamura Y, et al. Dopamine-induced protection of striatal neurons against kainate receptor-mediated glutamate cytotoxicity in vitro. Brain Res. 1994;655:61-9.

Andersen PH. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol. 1988;146:113-20.

Arnold SA, Hagg T. Serotonin 1A receptor agonist increases species- and

1
2
3 region-selective adult CNS proliferation, but not through CNTF. Neuropharmacology.
4
5
6 2012;63:1238-47.
7

8
9
10
11
12 Baker SA, Baker KA, Hagg T. Dopaminergic nigrostriatal projections regulate neural
13
14 precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci.
15
16
17
18 2004;20:575-9.
19
20
21
22
23
24

25 Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, et al.
26
27
28 Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate
29
30 gyrus-derived neural precursor cells through GSK-3beta and beta-catenin/TCF pathway.
31
32
33
34 Neuropsychopharmacology. 2009;34:805-15.
35
36
37
38
39
40

41 Borta A, Hoglinger GU. Dopamine and adult neurogenesis. J Neurochem.
42
43
44 2007;100:587-95.
45
46
47
48
49
50

51 Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al.
52
53
54 Radioreceptor binding profile of the atypical antipsychotic olanzapine.
55
56
57 Neuropsychopharmacology. 1996;14:87-96.
58
59
60
61
62
63
64
65

1
2
3
4
5
6 Chen J, Collins GT, Levant B, Woods J, Deschamps JR, Wang S. CJ-1639: A Potent and
7
8
9 Highly Selective Dopamine D3 Receptor Full Agonist. ACS Med Chem Lett.
10
11
12
13 2011;2:620-5.
14
15
16

17
18
19 Cooper SJ, Francis J, Rusk IN. The anorectic effect of SK&F 38393, a selective
20
21
22 dopamine D1 receptor agonist: a microstructural analysis of feeding and related
23
24
25 behaviour. Psychopharmacology (Berl). 1990;100:182-7.
26
27
28

29
30
31 D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of
32
33
34 action of antidepressant drugs. Eur J Pharmacol. 2000;405:365-73.
35
36
37

38
39
40
41 D'Haenen H A, Bossuyt A. Dopamine D2 receptors in depression measured with single
42
43
44 photon emission computed tomography. Biol Psychiatry. 1994;35:128-32.
45
46
47

48
49
50 David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al.
51
52
53 Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of
54
55
56 anxiety/depression. Neuron. 2009;62:479-93.
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 Dawirs RR, Hildebrandt K, Teuchert-Noodt G. Adult treatment with haloperidol
7
8
9 increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm.
10
11
12 1998;105:317-27.
13
14
15

16
17
18
19 Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and
20
21 antidepressants. Biol Psychiatry. 2006;59:1136-43.
22
23
24

25
26
27
28 Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant
29
30 treatment. Neuropsychopharmacology. 2001;25:836-44.
31
32
33

34
35
36
37
38 Egeland M, Zhang X, Millan MJ, Mocaer E, Svenningsson P. Pharmacological or
39
40 genetic blockade of the dopamine D3 receptor increases cell proliferation in the
41
42 hippocampus of adult mice. J Neurochem. 2012.
43
44
45

46
47
48
49
50 Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the
51
52 adult brain. Proc Natl Acad Sci U S A. 2006;103:8233-8.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Gambarana C, Ghiglieri O, Tagliamonte A, D'Alessandro N, de Montis MG. Crucial role
4
5
6 of D1 dopamine receptors in mediating the antidepressant effect of imipramine.
7

8
9
10 Pharmacol Biochem Behav. 1995;50:147-51.
11
12

13
14
15
16 Gasbarri A, Sulli A, Packard MG. The dopaminergic mesencephalic projections to the
17
18
19 hippocampal formation in the rat. Prog Neuropsychopharmacol Biol Psychiatry.
20
21
22 1997;21:1-22.
23
24
25

26
27
28 Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, et al. Dopamine
29
30
31 depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci.
32
33
34 2004;7:726-35.
35
36
37

38
39
40
41 Inoue T, Kitaichi Y, Masui T, Nakagawa S, Boku S, Tanaka T, et al. Pramipexole for
42
43
44 stage 2 treatment-resistant major depression: an open study. Prog
45
46
47 Neuropsychopharmacol Biol Psychiatry. 2010;34:1446-9.
48
49
50

51
52
53
54 Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, et al. Bromocriptine
55
56
57 treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol
58
59
60
61
62
63
64
65

1
2
3 Psychiatry. 1996;40:151-3.
4
5
6
7

8
9 Kempermann G. Adult neurogenesis : stem cells and neuronal development in the adult
10 brain. New York: Oxford University Press; 2006.
11
12
13
14
15
16
17

18 Khaindrava V, Salin P, Melon C, Ugrumov M, Kerkerian-Le-Goff L, Daszuta A. High
19 frequency stimulation of the subthalamic nucleus impacts adult neurogenesis in a rat
20 model of Parkinson's disease. Neurobiol Dis. 2011;42:284-91.
21
22
23
24
25
26
27
28
29
30

31 Kippin TE, Kapur S, van der Kooy D. Dopamine specifically inhibits forebrain neural
32 stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Kitagawa K, Kitamura Y, Miyazaki T, Miyaoka J, Kawasaki H, Asanuma M, et al.
Effects of pramipexole on the duration of immobility during the forced swim test in
normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol.
2009;380:59-66.

1
2
3 Li A, Guo H, Luo X, Sheng J, Yang S, Yin Y, et al. Apomorphine-induced activation of
4
5
6 dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes
7
8
9 survival of dopaminergic neurons. *FASEB J.* 2006;20:1263-5.
10
11
12

13
14
15
16 Li YF, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang HT. Antidepressant- and
17
18
19 anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend
20
21
22 on cyclic AMP response element binding protein-mediated neurogenesis in the
23
24
25 hippocampus. *Neuropsychopharmacology.* 2009;34:2404-19.
26
27
28

29
30
31 Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment
32
33
34 increases neurogenesis in adult rat hippocampus. *J Neurosci.* 2000;20:9104-10.
35
36
37

38
39
40
41 Masuda T, Nakagawa S, Boku S, Nishikawa H, Takamura N, Kato A, et al.
42
43
44 Noradrenaline increases neural precursor cells derived from adult rat dentate gyrus
45
46
47 through beta2 receptor. *Prog Neuropsychopharmacol Biol Psychiatry.* 2012;36:44-51.
48
49
50

51
52
53
54 Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al.
55
56
57 Lower dopamine transporter binding potential in striatum during depression.
58
59
60

61
62
63
64
65

1
2
3 Neuroreport. 2001;12:4121-5.
4
5
6
7
8

9
10 Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, et
11
12 al. S33138
13

14
15 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-
16
17 yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist
18
19 and potential antipsychotic agent: I. Receptor-binding profile and functional actions at
20
21
22
23
24
25 G-protein-coupled receptors. J Pharmacol Exp Ther. 2008;324:587-99.
26
27
28
29
30

31
32 Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from
33
34
35 structure to function. Physiol Rev. 1998;78:189-225.
36
37
38
39
40

41
42 Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB. Dihydroxidine, a
43
44
45 novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther.
46
47
48 1992;262:383-93.
49
50
51
52
53

54
55 Mu Y, Zhao C, Gage FH. Dopaminergic modulation of cortical inputs during maturation
56
57
58 of adult-born dentate granule cells. J Neurosci. 2011;31:4113-23.
59
60
61
62
63
64
65

1
2
3
4
5
6 Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, et al. Regulation of
7
8
9 neurogenesis in adult mouse hippocampus by cAMP and the cAMP response
10
11
12 element-binding protein. J Neurosci. 2002;22:3673-82.
13
14
15
16
17

18
19 Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ. Receptor affinities of dopamine
20
21
22 D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol. 2003;474:137-40.
23
24
25
26
27

28
29 O'Keefe GC, Barker RA, Caldwell MA. Dopaminergic modulation of neurogenesis in
30
31
32 the subventricular zone of the adult brain. Cell Cycle. 2009a;8:2888-94.
33
34
35
36
37

38
39 O'Keefe GC, Tyers P, Aarsland D, Dalley JW, Barker RA, Caldwell MA.
40
41
42 Dopamine-induced proliferation of adult neural precursor cells in the mammalian
43
44
45 subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A.
46
47
48 2009b;106:8754-9.
49
50
51
52
53

54
55 Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur
56
57
58 Neuropsychopharmacol. 2006;16:391-402.
59
60
61
62
63
64
65

1
2
3
4
5
6 Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of
7
8
9 hippocampal neurogenesis for the behavioral effects of antidepressants. Science.
10
11
12 2003;301:805-9.
13
14
15

16
17
18 Sasaki T, Kitagawa K, Omura-Matsuoka E, Todo K, Terasaki Y, Sugiura S, et al. The
19
20
21 phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal
22
23
24 neurons after ischemia. Stroke. 2007;38:1597-605.
25
26
27

28
29
30 Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates
31
32
33 of dopamine D2 binding in depression. Psychol Med. 1997;27:1247-56.
34
35
36

37
38
39 Simpson JA, Aarons L, White NJ. How can we do pharmacokinetic studies in the
40
41
42 tropics? Trans R Soc Trop Med Hyg. 2001;95:347-51.
43
44
45

46
47
48 Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action.
49
50
51 Int Clin Psychopharmacol. 1997;12 Suppl 3:S7-14.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Winner B, Desplats P, Hagl C, Klucken J, Aigner R, Ploetz S, et al. Dopamine receptor
4
5
6 activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol.
7
8
9 2009;219:543-52.
10

11
12
13
14
15
16 Yang P, Arnold SA, Habas A, Hetman M, Hagg T. Ciliary neurotrophic factor mediates
17
18
19 dopamine D2 receptor-induced CNS neurogenesis in adult mice. J Neurosci. 2008; 28:
20
21
22 2231-41.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table Legends

Table.1 The affinities of drugs for D1-like and D2-like receptor of rat striatum.

Table. 2 The PCR primer sequence and product size

Figure Legends

Fig. 1. Effect of dopamine on ADP proliferation. ADPs were incubated in the proliferation medium with dopamine for 3 days. The cell number of ADPs was determined using Alamar Blue assay. Data are presented as percentages of control. Data are expressed as mean $\pm$ SEM from six independent experiments. $**p < 0.01$, $*p < 0.05$ compared with control. ADP, adult rat dentate gyrus-derived neural precursor cell. Cont, control.

Fig. 2. mRNA expression pattern of GAPDH as an internal control and dopamine receptors on ADPs. The RT-PCR products were analyzed in 3 % agarose gels stained with ethidium bromide with a standard DNA marker.

Fig. 3. Effects of dopamine receptor antagonists on ADP proliferation. (A, C) The effect of D1-like receptor antagonist R-SCH23390 or D2-like receptor antagonist sulpiride on ADP proliferation. The cells were incubated with them for 3 days. (B, D) The effect of R-SCH23390 or sulpiride on dopamine-promoted ADP proliferation. The ADPs were incubated with R-SCH23390 or sulpiride for 1 h prior to adding 30 μ M dopamine,

1
2
3 followed by their incubation for 3days. Data are expressed as mean $\pm$ SEM from three
4
5
6 or four independent experiments. $**p < 0.01$ compared with control, $##p < 0.01$, $#p$
7
8
9 < 0.05 compared with 30 μ M dopamine alone. Cont, control.
10
11
12
13
14
15

16 Fig. 4. Effects of dopamine receptor agonists on ADP proliferation. (A,B) The effect of
17
18 D1-like receptor agonist on ADP proliferation. The ADPs were incubated with
19
20 ($\pm$)-SKF38393 or ($\pm$)-SKF81297 for 3 days. (C-E) The effect of D2-like receptor
21
22 agonists on ADP proliferation. The ADPs were incubated either with quipirole,
23
24
25 pramipexole or bromocriptine for 3 days. Data are expressed as mean $\pm$ SEM from three
26
27
28
29 or four independent experiments. $**p < 0.01$ compared with control. Cont, control.
30
31
32
33
34
35
36
37

38 Fig. 5. Effects of dopamine receptor agonists on the proliferation of newborn cell in
39
40 adult rat hippocampus. Rats were received single injection of BrdU after ($\pm$)-SKF39383
41
42 or pramipexole treatment for 21 days, and were killed 24 h after BrdU injection. Shown
43
44
45 are representative photomicrographs of BrdU positive cells (arrows) in hippocampus
46
47
48 from vehicle (A), 10 mg/kg ($\pm$)-SKF38393 (B) and 1 mg/kg pramipexole (C). The
49
50
51 histogram shows the quantification of BrdU-positive cells in the SGZ (D, F and H) and
52
53
54 hilus (E, G and I). The data are presented as the mean $\pm$ SEM number of BrdU-positive
55
56
57
58
59
60
61
62
63
64
65

cells in the subgranular zone (SGZ) or hilus of the hippocampus (n=6-9). Scale bars:
100 μ m.

Fig. 6. Effects of dopamine receptor agonists on the survival of newborn cells in the adult rat hippocampus. Rats were received chronic administration of ($\pm$)-SKF38393 or pramipexole for 21 days after single BrdU injection (75 mg/kg). Rats were killed 24 h after the last administration. Shown are representative photomicrographs of BrdU positive cells (arrows) in the hippocampus from vehicle (A), 10 mg/kg ($\pm$)-SKF38393 (B) and 1 mg/kg pramipexole (C). The Histogram shows the quantification of BrdU positive cells in the GCL (D and F) and hilus (E and G). The data are presented as the mean $\pm$ SEM number of BrdU positive cells. (D) $\dagger\dagger p < 0.01$, $\dagger p < 0.05$ compared with vehicle (Steel test). (E) $**p < 0.01$ compared with vehicle (n=6-9). Scale bars: 20 μ m.

Figure.1

Figure.2

Figure.3

Figure4
[Click here to download high resolution image](#)

Figure.4

Figure5
[Click here to download high resolution image](#)

Figure.5

Figure.6

Table 1

DA receptor ligand	Ki (nM)	
	D1-like receptor	D2-like receptor
DA	500	70
(±)-SKF38393	18	9300
(±)-SKF81297	1.9	1270
Quinpirole	>5000	720
Pramipexole	>10000	39
Bromocriptine	>10000	8
SCH23390	0.14	895
Sulpiride	>10000	70

Table 1

Primers		Sequences	Product size (bp)
GAPDH	Forward	5'-AGCTGGTCATCAATGGGAAA -3'	63
	Reverse	5'-ATTTGATGTTAGCGGGATCG -3'	
D1	Forward	5'-TCCAGAAAGGAAGGGTAGGAG-3'	80
	Reverse	5'- CCTTTCCAATCTGAAAAGCTGCT -3'	
D2	Forward	5'-TGAACAGGCGGAGAATGG-3'	70
	Reverse	5'-CTGGTGCTTGACAGCATCTC-3'	
D3	Forward	5'-GATGGTGGTCATTGTGCTTG-3'	74
	Reverse	5'-GGGTATTAAGAACGTGAGTCAGGA-3'	
D4	Forward	5'-CCTCCATCTTCAACCTGTGC-3'	76
	Reverse	5'-TGCTGGTTGTAGCGCAGT-3'	
D5	Forward	5'-CATGTCTCAAATCTCTCCAACG-3'	69
	Reverse	5'-CAGTCAAGCTCCCAGACAGA-3'	